Primlintide/leptin combo produces 12.7% weight loss, says Amylin

San Diego, USA-based Amylin Pharmaceuticals has announced positive results from a 24-week proof-of-concept study with pramlintide, an analog of human amylin, and recombinant human leptin (r-metHuLeptin; metreleptin) combination treatment in overweight or obese subjects. At study end, pramlintide/metreleptin treatment reduced body weight on average 12.7%, significantly more than treatment with pramlintide alone (8.4 %; p<0.001).

Subjects treated with pramlintide/metreleptin lost a median of 25 pounds from study start compared with an average of 17 pounds for those treated with pramlintide alone. People receiving pramlintide/metreleptin had continuous weight loss through the end of the study compared to those treated with pramlintide alone, whose weight loss had stabilized towards the end of the study. At study start, the average weight of study participants was around 205 pounds.

Consistent with previous clinical experience with pramlintide and metreleptin as single agents, mylin says that the most common side effects seen with the combination treatment were injection site adverse events and nausea, which were mostly mild to moderate and transient in nature.